PARP-1 expression in breast cancer including BRCA1-associated, triple neg- ative and basal-like tumors: possible implica- tions for PARP-1 inhibitor therapy. Breast Can- cer Res Treat 2011; 127: 861-869.Pawel Domagala,Tomasz Huzarski,Jan Lubinski.PARP-1 expression in breast cancer including ...
The poly (ADP-ribose) polymerase-1 (PARP-1) enzyme is an important target in the treatment of breast cancer. Currently, treatment options include the drugs Olaparib, Niraparib, Rucaparib, and Talazoparib; however, these drugs can cause severe side effects including hematological toxicity and c...
Cancer remains one of the leading causes of death worldwide, with the rising incidence of breast cancer being a significant public health concern. Poly (ADP-ribose) polymerase-1 (PARP-1) has emerged as a promising therapeutic target for breast cancer treatment due to its crucial role in DNA ...
including BRCA1/2 mutant breast cancer, responses are usually transient requiring the deployment of combination therapies for optimal efficacy. Here we thus explore mechanisms underlying sensitivity and resistance to PARPi using two intrinsically PARPi sensitive (T22) and resistant (T...
Shanghai, March 26, 2024 – BioDuro-Sundia's partner, DigmBio, a South Korean biotechnology company, announced itsselective PARP1 inhibitor for the treatment of triple-negative breast cancerhas been approved by Korea Food and Drug Administration (MFDS) for Investigational New Drug (IND) applicatio...
Preclinical characterization of AZD5305, a next-generation, highly selective PARP1 inhibitor and trapper. Clin Cancer Res. 2022;28(21):4724-4736. doi:10.1158/1078-0432.CCR-22-0301 LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. Exploring and comparing adverse events between PARP inhibitors....
MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation. Investigational new drugs 30, 2113–2120, https://doi.org/10.1007/s10637-011-9770-x (2012). Article CAS PubMed Google Scholar Schreiber, V., Dantzer, F. & Ame, J. C...
PARP inhibitor combination therapy - ScienceDirect In 2014, olaparib (Lynparza) became the first PARP (Poly(ADP-ribose) polymerase) inhibitor to be approved for the treatment of cancer. When used as single ... Amy Dréan a,Christopher J. Lord a,Alan Ashworth b - 《Critical Reviews in Onco...
The first clinical trial, a phase III trial, of the PARP inhibitor iniparib in triple negative breast cancer failed, as did a phase II trial in non-small cell lung cancer (NSCLC) (Novello et al., 2014; O'Shaughnessy et al., 2014). It was later shown that iniparib was not a true ...
PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib. Gynecol. Oncol. 2019, 155, 144–150. [Google Scholar] [CrossRef] Mann, M.; Kumar, S.; Sharma, A.; Chauhan, S.S.; Bhatla, N.; Kumar, S.; Kumar, L. PARP-1 inhibitor modulate β-catenin signaling ...